MEI Pharma, Inc. (MEIP) |
|
0.2289 -0.001 (-0.44%)
|
03-31 16:00 |
|
Open: |
0.2273 |
Pre. Close: |
0.2299 |
|
High:
|
0.233 |
Low:
|
0.222 |
|
Volume:
|
449,962 |
Market Cap:
|
31(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:24 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.28  One year: 0.3 |
| Support: |
Support1: 0.2 Support2: 0.17 |
| Resistance: |
Resistance1: 0.24 Resistance2: 0.25 |
| Pivot: |
0.24  |
| Moving Average: |
MA(5): 0.23 MA(20): 0.24
MA(100): 0.28 MA(250): 0.41 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 19 %D(3): 20.8 |
| RSI: |
RSI(14): 41.1 |
| 52-week: |
High: 0.69 Low: 0.2 |
| Average Vol(K): |
3-Month: 1,093 (K) 10-Days: 816 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MEIP ] has closed above bottom band by 18.8%. Bollinger Bands are 58.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.23 - 0.23 |
0.23 - 0.24 |
|
Low:
|
0.22 - 0.22 |
0.22 - 0.22 |
|
Close:
|
0.23 - 0.23 |
0.23 - 0.23 |
|
Company Description |
|
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. |
Headline News |
Thu, 23 Feb 2023
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates - Yahoo Finance
Thu, 23 Feb 2023
MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether ... - Business Wire
Thu, 23 Feb 2023
MEI Pharma and Infinity Pharma ink all-stock merger deal (NASDAQ ... - Seeking Alpha
Fri, 17 Feb 2023
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP) - Simply Wall St
Thu, 09 Feb 2023
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and ... - Business Wire
Fri, 30 Dec 2022
Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP) - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
133 (M) |
| Shares Float |
124 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
37.2 (%) |
|
Shares Short
|
3,480 (K) |
|
Shares Short P.Month
|
3,820 (K) |
Stock Financials |
|
EPS
|
-0.53 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.15 |
|
EPS Est Next Year
|
-1.38 |
|
Book Value (p.s.)
|
0.64 |
|
Profit Margin (%)
|
-49.8 |
|
Operating Margin (%)
|
-75.2 |
|
Return on Assets (ttm)
|
-16.5 |
|
Return on Equity (ttm)
|
-51.3 |
|
Qtrly Rev. Growth
|
176.6 |
|
Gross Profit (p.s.)
|
0.3 |
|
Sales Per Share
|
0.46 |
|
EBITDA (p.s.)
|
-0.36 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-70 (M) |
|
Levered Free Cash Flow
|
-21 (M) |
Stock Valuations |
|
PE Ratio
|
-0.44 |
|
PEG Ratio
|
5.3 |
|
Price to Book value
|
0.35 |
|
Price to Sales
|
0.48 |
|
Price to Cash Flow
|
-0.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
